Associated Papers
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
33133066 (PubMed )
Supplement: Table_1.xlsx › Resistance-ABL1
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
Zabriskie MS et al.
Cancer Cell, 2014
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.
Khorashad JS et al.
Blood, 2013
Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
Jiang X et al.
Journal of the National Cancer Institute, 2007
Select a paper to view details